Far from costing British lives, as Aditya Chakrabortty suggests (What will be the cost of Keir Starmer’s new medicines deal with Donald Trump? British lives, 11 December), the UK-US medicines agreement is designed to support NHS patients by improving access to new and innovative treatments.
The agreement raises the baseline threshold used by the National Institute for Health and Care Excellence to assess the cost-effectiveness for new medicines, enabling more treatments to be considered for NHS use.
